# Roca Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/roca-therapeutics

- Industry: Biotechnology
- Headquarters: France
- Website: www.roca-therapeutics.org
- Total disclosed funding: $0.6M
- Latest round: Seed (Apr 28, 2022)
- Investors on record: 1

## About

Based in France and founded in 2021, Roca Therapeutics is a biotech startup specializing in the discovery and development of small molecules addressing severe life-threatening disorders. Maeva Dufies (CEO and CSO), Zaki Sellam, Gilles Pagès, Rachid Benhida, and Cyril Ronco are the co-founders of the company. In September 2022, Roca Therapeutics raised Seed funding from 3B Future Health Fund and SATT Sud-Est.

The company provides its products, including RCT001 (Metastatic Uveal Melanoma), which is the treatment for a primary and metastatic form of uveal melanoma; and RCT002 (Neovascular Complications), which is the treatment and prevention of neovascular complications after proton therapy, such as glaucoma and retinopathy. The firm's partners include Ircan, Inserm, I-Lab, Bpifrance, Cnrs, and more.

The organization plans to use the September 2022 funding to develop its lead clinical candidate RCT001 (Metastatic Uveal Melanoma) until IND/CTA readiness in 2023 and to further expand the company’s portfolio of assets with the nomination of a second clinical candidate for Neovascular Glaucoma associated with uveal melanoma.

## Funding rounds

- Seed, Apr 28, 2022, $0.6M — 3B Future Health Fund

## Investors

- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Seed